Oprozomib (OPZ) and Dexamethasone (DEX) in Patients (Pts) With Relapsed and/or Refractory Multiple Myeloma (RRMM): Updated Results From a Phase 1b/2, Multicenter, Open-Label Study

Claudia Prada(Dana-Farber Cancer Institute), Parameswaran Hari(Medical College of Wisconsin), Paul G. Richardson(Harvard University), Kenneth H. Shain(Moffitt Cancer Center), Muneer H. Abidi(Spectrum Health), Linda Neuman, Hansen Wong(Amgen (United States)), Peter M. Voorhees(Levine Cancer Institute), Nashat Gabrail(Gabrail Cancer Center), S. Dixon(Amgen (United States)), Ralph V. Boccia(Center for Cancer and Blood Disorders), Jeffrey A. Zonder(The Barbara Ann Karmanos Cancer Institute)
Clinical Lymphoma Myeloma & Leukemia
September 1, 2015
10.1016/j.clml.2015.07.569
Cited by 5

Related Papers

A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma
|New England Journal of Medicine|2003|2.6k
International uniform response criteria for multiple myeloma
|Leukemia|2006|2.6k
Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study
|The Lancet|2021|1.7k
Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
|New England Journal of Medicine|2012|1.2k
Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
|New England Journal of Medicine|2016|1.1k